Author： Ferdinand Keith C
Publisher： Informa Healthcare
ISSN： 1465-6566
Source： Expert Opinion on Pharmacotherapy, Vol.6, Iss.11, 2005-09, pp. : 1897-1910
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
A Risk-Benefit Assessment of Abciximab in Angioplasty
By Kleiman N.S.
Drug Safety, Vol. 20, Iss. 1, 1999-01 ,pp. :
Access to resources
Recommend
A Risk-Benefit Assessment of Amifostine in Cytoprotection
By Mabro M.
Drug Safety, Vol. 21, Iss. 5, 1999-11 ,pp. :
A Risk-Benefit Assessment of Antileukotrienes in Asthma
By Smith L.J.
Drug Safety, Vol. 19, Iss. 3, 1998-09 ,pp. :
A Risk-Benefit Assessment of Oxytocics in Obstetric Practice
Drug Safety, Vol. 20, Iss. 4, 1999-04 ,pp. :
A Risk-Benefit Assessment of Aprotinin in Cardiac Surgical Procedures
Drug Safety, Vol. 18, Iss. 1, 1998-01 ,pp. :